170 related articles for article (PubMed ID: 32988214)
1. The Role of Volume in the Perceptibility of Topical Vaginal Formulations: User Sensory Perceptions and Experiences of Heterosexual Couples During Vaginal Sex.
Guthrie KM; Fava JL; Vargas SE; Rosen RK; Shaw JG; Kojic EM; Ham AS; Rohan LC; Katz D; Panameño A; Colleran C; Friend DF; Buckheit KW; Buckheit RW
AIDS Res Hum Retroviruses; 2020 Dec; 36(12):1059-1070. PubMed ID: 32988214
[TBL] [Abstract][Full Text] [Related]
2. Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties.
Morrow KM; Fava JL; Rosen RK; Vargas S; Shaw JG; Kojic EM; Kiser PF; Friend DR; Katz DF;
AIDS Res Hum Retroviruses; 2014 Jan; 30(1):78-91. PubMed ID: 24180360
[TBL] [Abstract][Full Text] [Related]
3. Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design.
Guthrie KM; Dunsiger S; Vargas SE; Fava JL; Shaw JG; Rosen RK; Kiser PF; Kojic EM; Friend DR; Katz DF
AIDS Res Hum Retroviruses; 2016; 32(10-11):1022-1030. PubMed ID: 26942455
[TBL] [Abstract][Full Text] [Related]
4. User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides.
Morrow KM; Underhill K; van den Berg JJ; Vargas S; Rosen RK; Katz DF
Arch Sex Behav; 2014 Oct; 43(7):1459-67. PubMed ID: 24452632
[TBL] [Abstract][Full Text] [Related]
5. Vaginal film for prevention of HIV: using visual and tactile evaluations among potential users to inform product design.
Guthrie KM; Rohan L; Rosen RK; Vargas SE; Shaw JG; Katz D; Kojic EM; Ham AS; Friend D; Buckheit KW; Buckheit RW
Pharm Dev Technol; 2018 Mar; 23(3):311-314. PubMed ID: 28592183
[TBL] [Abstract][Full Text] [Related]
6. Designing Dual Compartment HIV Prevention Products: Women's Sensory Perceptions and Experiences of Suppositories for Rectal and Vaginal Use.
Guthrie KM; Rosen RK; Guillen M; Ramirez JJ; Vargas SE; Fava JL; Ham AS; Katz DF; Cu-Uvin S; Tumilty S; Smith KA; Buckheit KW; Buckheit RW
AIDS Res Hum Retroviruses; 2022 Jul; 38(7):601-610. PubMed ID: 34544269
[TBL] [Abstract][Full Text] [Related]
7. Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings.
Rosen RK; van den Berg JJ; Vargas SE; Senocak N; Shaw JG; Buckheit RW; Smith KA; Guthrie KM
Contraception; 2015 Dec; 92(6):596-601. PubMed ID: 26276246
[TBL] [Abstract][Full Text] [Related]
8. User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences.
Guthrie KM; Rosen RK; Vargas SE; Getz ML; Dawson L; Guillen M; Ramirez JJ; Baum MM; Vincent KL
PLoS One; 2018; 13(5):e0197269. PubMed ID: 29758049
[TBL] [Abstract][Full Text] [Related]
9. "Set it and forget it": women's perceptions and opinions of long-acting topical vaginal gels.
van den Berg JJ; Rosen RK; Bregman DE; Thompson LA; Jensen KM; Kiser PF; Katz DF; Buckheit K; Buckheit RW; Morrow KM
AIDS Behav; 2014 May; 18(5):862-70. PubMed ID: 24248674
[TBL] [Abstract][Full Text] [Related]
10. Acceptability and performance of a nonwoven device for vaginal drug delivery among women and their male partners in KwaZulu-Natal, South Africa.
Hart CW; Joanis C; Hartmann M; Milford C; Smit J; Beksinska M; Rambally-Greener L; Pienaar J; Mabude Z; Butterworth GAM; Sokal D; Jenkins D
Eur J Contracept Reprod Health Care; 2019 Oct; 24(5):390-398. PubMed ID: 31517545
[No Abstract] [Full Text] [Related]
11. Design aspects of vaginal applicators that influence acceptance among target users.
Bakke AJ; Zaveri T; Higgins MJ; Ziegler GR; Hayes JE
Sci Rep; 2021 May; 11(1):9802. PubMed ID: 33963262
[TBL] [Abstract][Full Text] [Related]
12. Qualitative exploration of intrinsic and extrinsic factors that influence acceptability of semisoft vaginal suppositories.
Zaveri T; Powell KA; Guthrie KM; Bakke AJ; Ziegler GR; Hayes JE
BMC Womens Health; 2018 Oct; 18(1):170. PubMed ID: 30342510
[TBL] [Abstract][Full Text] [Related]
13. Specific microbicides in the prevention of HIV infection.
Kelly CG; Shattock RJ
J Intern Med; 2011 Dec; 270(6):509-19. PubMed ID: 21917029
[TBL] [Abstract][Full Text] [Related]
14. Clinical development of microbicides for the prevention of HIV infection.
D'Cruz OJ; Uckun FM
Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).
Robinson JA; Marzinke MA; Bakshi RP; Fuchs EJ; Radebaugh CL; Aung W; Spiegel HM; Coleman JS; Rohan LC; Hendrix CW
AIDS Res Hum Retroviruses; 2017 Apr; 33(4):339-346. PubMed ID: 27809557
[TBL] [Abstract][Full Text] [Related]
16. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo.
Trifonova RT; Pasicznyk JM; Fichorova RN
Antimicrob Agents Chemother; 2006 Dec; 50(12):4005-10. PubMed ID: 17030562
[TBL] [Abstract][Full Text] [Related]
17. Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study.
Luecke EH; Cheng H; Woeber K; Nakyanzi T; Mudekunye-Mahaka IC; van der Straten A;
J Int AIDS Soc; 2016; 19(1):20875. PubMed ID: 27247202
[TBL] [Abstract][Full Text] [Related]
18. On-demand microbicide products: design matters.
Patel SK; Rohan LC
Drug Deliv Transl Res; 2017 Dec; 7(6):775-795. PubMed ID: 28589452
[TBL] [Abstract][Full Text] [Related]
19. Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.
Adams JL; Kashuba AD
Best Pract Res Clin Obstet Gynaecol; 2012 Aug; 26(4):451-62. PubMed ID: 22306523
[TBL] [Abstract][Full Text] [Related]
20. Acceptability of a non-woven device for vaginal drug delivery of microbicides or other active agents.
Joanis CL; Hart CW
AIDS Behav; 2010 Jun; 14(3):600-6. PubMed ID: 20049522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
